Evidence map›Paper›PMID 42666526›Full record

ReviewChemical science2026

The advent of molecular nanocarbon biology.

Kazuma Amaike, Ayaka Ueda, Kenichiro Itami

Abstract readReview
In one paragraph

Review in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kazuma AmaikeRIKEN Pioneering Research Institute, RIKEN Wako Saitama 351-0198 Japan kazuma.amaike@riken.jp kenichiro.itami@riken.jp.
Ayaka UedaRIKEN Pioneering Research Institute, RIKEN Wako Saitama 351-0198 Japan kazuma.amaike@riken.jp kenichiro.itami@riken.jp.
Kenichiro ItamiRIKEN Pioneering Research Institute, RIKEN Wako Saitama 351-0198 Japan kazuma.amaike@riken.jp kenichiro.itami@riken.jp.ORCID https://orcid.org/0000-0001-5227-7894

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular nanocarbons, including polycyclic aromatic hydrocarbons, cycloparaphenylenes, and carbon nanobelts, have emerged as structurally well-defined carbon-rich molecules with unique photophysical, electronic, and topological properties. Recent advances in synthetic organic chemistry have greatly expanded the accessible structural diversity of molecular nanocarbons, accelerating their exploration not only in materials science but also in the biological sciences. In this perspective, we summarize recent progress in the biological applications of molecular nanocarbons. These studies are beginning to establish molecular nanocarbons as a versatile platform at the interface of synthetic chemistry and biology. Continued advances in molecular design, functionalization, and biological evaluation should further expand their roles in imaging, delivery, therapeutics, and biocatalysis, thereby opening new directions for both molecular nanocarbon science and chemical biology. Together, these advances mark the emergence of molecular nanocarbon biology, a new research direction in which precisely synthesized carbon frameworks are designed to interact with living systems in controlled and functional ways.

Identifiers

PMID42666526
PMCPMC13522950

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.